Linda Wernevik
BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials.
Journal: Journal of hepatology
Published: August 20, 2024
Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide.
Journal: British journal of clinical pharmacology
Published: August 25, 2023
A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II.
Journal: CPT: pharmacometrics & systems pharmacology
Published: July 25, 2022
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.
Journal: British journal of clinical pharmacology
Published: February 22, 2022
Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.
Journal: Clinical and translational science
Published: February 18, 2022
An oral antisense oligonucleotide for PCSK9 inhibition.
Journal: Science translational medicine
Published: October 09, 2020
Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
Journal: Clinical and translational science
Published: July 22, 2019
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
Journal: British journal of clinical pharmacology
Published: March 22, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026